Envisia's ENV515 matches Travatan Z in glaucoma study

Envisia Therapeutics Inc. (Research Triangle Park, N.C.) said ENV515 met the primary endpoint in a Phase IIa

Read the full 173 word article

How to gain access

Continue reading with a
two-week free trial.